Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia

NCT01230775 | Completed Phase 3 DMC

• 1 other identifier: AOP13007
• Study Type: interventional
• Target: 146
• Locations: 9 countries
• Sites: 37

Brief Summary

This is a multicenter, phase III, randomized, subject and sponsor-blinded, placebo-controlled study to determine the treatment effect of "Anagrelide retard" in subjects with Essential Thrombocythaemia (ET) at "defined risk" (definition of risk criteria: see Inclusion Criteria Section 5.1) The study is planned as a 2-stage procedure according to Bauer and Köhne: After recruitment of 140 subjects an interim analysis with re-assessment of sample size is planned in an adaptive manner. As the confirmatory analysis will be based on a time-to-event evaluation (i.e. time to 1st clinically significant ET related event), there is no stipulated observation time identically applying for all subjects. Yet, with an interim analysis being performed after having recruited 140 subjects - which is expected to be reached after 1 year - the estimated observation time for a subject in stage I will also be about 1 year. (Details are explained in the section "Statistical Considerations"). Subjects will be randomized in a 1:1 ratio to one of the following two arms: Group A: Anagrelide retard Group B: Placebo An a priori stratification is planned for the JAK-2 mutational status. For exploratory purposes a post hoc stratification is used for obtaining covariate adjusted results, for the following other potentially predictive factors: sex, age, Factor V Leiden, and BMI. Dosing will be started with 1 tablet per day for week 1 and will be titrated up according to response (platelet reduction) to 2 tablets in week 2. Dosing may be further increased or decreased according to platelet response in week 3 and 4. However, the maximum dose is 4 tablets (=8mg) per day. After week 4, the maximum dose to achieve optimal platelet counts (\<450 G/L) should be maintained (for visit schedule see study flow chart section IV). To verify a treatment response, platelet counts must be evaluated at every visit. The platelet count values will be withheld from the subjects for the duration of stage I or stage II respectively. The subjects have to agree explicitly to this procedure by signing the Informed Consent form. This is a patient and sponsor-blinded clinical study. The trial medical is packaged in the blinded fashion to keep the patient unaware (blinded) towards the actual treatment group they were randomized to. The sponsor functions (including medical monitor, pharmacovigilance manager, clinical project manager, trial data manager and trial statistician) with stay blinded in the course of the study until the database lock. Randomization scheme will be prepared by an independent statistician (not otherwise involved in the study), and will be stored securely with no access to it by the sponsor functions mentioned above. The process of randomization (provision of the individual drug-allocation information to the subjects) will be carried out by a trained staff by Harrison, in adherence to the procedures to keep the other blinded functions unaware of this information (blinded). Unblinding envelopes, which contain the treatment code per patient number for identification of treatment in case when a safety-relevant unblinding needed, will be stored at the sponsor's site. At the end of the study, verification of the extent of maintaining the blind by checking if the envelopes have been broken, will take place and will be properly documented. If the sealed envelope will broken to provide treatment identification, the date of breaking the code, the initials of the person who broke the code and the reason will be stated on the envelope. The operational details on the blinding procedures are outlined in the relevant working guidelines (ARETA Study Working Guideline for idv staff and ARETA Study Working Guideline for Harrison, each in its current version). Investigator will not be blinded in this study, i.e. in case of a medical need individual patient management will be driven by the full knowledge of the trial related interventions. For the case, the sponsor will need to unblind a patient (e.g. due to safety reasons), the above mentioned (in this section) envelopes will be used. Only treatment naïve subjects, in respect to cytoreductive drugs with confirmed diagnosis of ET (centralized re-evaluation according to WHO, 2008; see Section 6.2.1) and assessment of JAK-2 status (centralized re-evaluation of JAK-2 status; see Section 6.2.2) will be enrolled. As described above, stage I of the study will be considered as closed as soon as 140 subjects have been recruited. The duration of stage II depends on the result of the re-assessment of sample size. Once stage I is finished, stage I subjects will enter into an extension period for a maximum of three years.

Conditions

Essential Thrombocythaemia

Outcome Measures

Primary Outcomes (1)

• Time to 1st clinically significant ET related event

  beginning 2012

Secondary Outcomes (1)

• Efficacy and safety

  end 2013

Study Arms (2)

Anagrelide retard

EXPERIMENTAL

Week 1: 1x1 tablet/d of "Anagrelide retard" (1 tablet = 2mg; total dose = 2mg/d will be administered in week 1. Week 2 "Anagrelide retard": Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2. Week 3 - Week 4 "Anagrelide retard" In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day. Maintenance Phase "Anagrelide retard" During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range. Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d

Drug: Anagrelide retard

Placebo

PLACEBO COMPARATOR

Week 1: 1. x1 tablet/d of Placebo will be administered in week 1. Placebo: 2. x1 tablet/d of placebo will be administered in week 2. Placebo: In week 3 and week 4 the maximum dose is 4 tablets per day. Placebo: In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period: Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/d

Drug: Placebo

Interventions

Anagrelide retard DRUG

Week 1: 1x1 tablet/d of "Anagrelide retard" (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1. Week 2 "Anagrelide retard": Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2. Week 3 - Week 4 "Anagrelide retard" In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day. Maintenance Phase "Anagrelide retard" During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range.

Anagrelide retard

Placebo DRUG

Week 1: 1. x1 tablet/d of placebo will be administered in week 1. Week 2 Placebo: 2. x1 tablet/d of placebo will be administered in week 2. Week 3 - Week 4 Placebo: In week 3 and week 4 the maximum dose is 4 tablets per day. Placebo: In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period: Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/

Placebo

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Willing and able to give written informed consent prior to any study specific procedures and able to comply with this protocol
• Male or female subjects aged between 18 and 60 years,
• Confirmed diagnosis of ET according to WHO-criteria 2008 (Appendix A) including assessment of JAK-2 status (central re-evaluation).
• Presence of predisposing risk factors for ET related events confirmed by clinical or laboratory results:
• Definition of subjects with potential risk for ET-related Events:
• \- Platelet count \< 1.000 G/L
• Additionally at least ONE of the following criteria has to be fulfilled:
• Subjects aged between 40 and 60 years or
• Subjects with ET and disease duration \> 3 years (Diagnosis of ET has to be at least 3 years ago and confirmed at time of screening) or
• Subjects with ONE of the following risk factors for thrombotic complications:
• JAK- 2 positivity
• Protein C and/or Protein S deficiency
• Antithrombin III deficiency
• Factor V Leiden or Prothrombin mutation
• Cardiovascular risk factors:

You may not qualify if:

• Diagnosis of any other myeloproliferative disorder
• High-risk status (age \> 60 years, platelet count ≥ 1.000 G/L, increase of platelet count \> 300 G/L within 3 month, history of thrombotic/haemorrhagic or ischemic complications).
• Any known cause for a secondary thrombocytosis
• Previous or current treatment of ET with cytoreductive therapy
• Diagnosis of any malignancy, apart from ET, within the last 3 years
• Known or suspected intolerance to the investigational product
• Known or suspected congestive heart failure
• WBC ≥ 15 G/L
• Severe renal impairment (creatinine clearance \<30 ml/min)
• Severe liver impairment (ALT or AST \>5 times normal)
• Clinically significant abnormal laboratory values (excluding markers of essential thrombocythaemia)
• Poorly controlled diabetes mellitus
• Infection with hepatitis B, hepatitis C or HIV
• Subjects with a history of drug/alcohol abuse (within the previous 2 years)
• Participation in another investigational study within 6 months prior to enrolment or for a longer duration if specified in local regulations

Sponsors & Collaborators

• AOP Orphan Pharmaceuticals AG: lead

Study Sites (37)

Uniklinik Innsbruck

Innsbruck, Austria

Location

Universitätsklinik für Innere Medizin III, Universitätsklinikum Salzburg

Salzburg, Austria

Location

Hanusch Krankenhaus

Vienna, Austria

Location

Sozialmedizinisches Zentrum Ost

Vienna, Austria

Location

Uniklinik für Innere Medizin I

Vienna, Austria

Location

University Multiprofile Hospital for Active Treatment "Dr Georgi Stranski"

Pleven, Bulgaria

Location

University Multiprofile Hospital for Active Treatment "Sveti Georgi"

Plovdiv, Bulgaria

Location

Multiprofile Hospital for Active Treatment, "Tokuda Hospital Sofia"

Sofia, Bulgaria

Location

National Specialized Hospital for Active Treatment of Hematological Diseases

Sofia, Bulgaria

Location

SHAT "Joan Pavel"

Sofia, Bulgaria

Location

Clinical Hospital Dubrava

Zagreb, Croatia

Location

Kauno Medicinos Universiteto Klinikos

Kaunas, Lithuania

Location

Klaipeda Hospital

Klaipėda, Lithuania

Location

Uniwersyteckie Centrum Kliniczne

Gdansk, Poland

Location

SP Szpital Kliniczny im. A. Mieleckiego

Katowice, Poland

Location

Wojewódzki Szpital Specjalistyczny

Rzeszów, Poland

Location

Specjalistyczny Szpital Miejski

Torùn, Poland

Location

Klinika Hematologiczna, Instytut Hematologii i Transfuzjologii

Warsaw, Poland

Location

Samodzielny Publiczny Centralny Szpital

Warsaw, Poland

Location

Clinical County Hospital "Dr. Constantin Opris"

Baia Mare, Romania

Location

"Coltea" Clinic Hospital

Bucharest, Romania

Location

"Fundeni" Clinical Institute

Bucharest, Romania

Location

University Emergency Hospital

Bucharest, Romania

Location

Emergency County Clinic Hospital

Sibiu, Romania

Location

Emergency County Hospital Târgu Mureș

Târgu Mureş, Romania

Location

State Medical Institution Territorial Clinical

Krasnodar, Russia

Location

Haematology Research Center of RAMS

Moscow, Russia

Location

Leningrad Regional Clinical Hospital

Saint Petersburg, Russia

Location

Russian scientific Research Institute for Hematology and Transfusiology

Saint Petersburg, Russia

Location

Saint Petersburg State Institution of Healthcare

Saint Petersburg, Russia

Location

Yaroslavl Regional Clinical Hospital

Yaroslavl, Russia

Location

University Hospital Bratislava

Bratislava, Slovakia

Location

Institute of Urgent and Recovery Surgery n.a.

Donetsk, Ukraine

Location

Kmelnitskiy Regional Hospital

Khmelnitskiy, Ukraine

Location

Institute of Haematology and Transfusiology

Kiev, Ukraine

Location

Scientific Center of Radiation Medicine AMS of Ukraine

Kiev, Ukraine

Location

Lviv Blood Pathology Institute

Lviv, Ukraine

Location

MeSH Terms

Conditions

Thrombocythemia, Essential

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Thrombocytosis; Blood Platelet Disorders; Myeloproliferative Disorders; Bone Marrow Diseases; Hemorrhagic Disorders

Study Officials

• Barbara Grohmann-Izay, MD

  AOP Orphan Pharmaceuticals AG

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 28, 2010
• First Posted: October 29, 2010
• Study Start: December 1, 2010
• Primary Completion: January 1, 2015
• Study Completion: January 1, 2015
• Last Updated: May 26, 2016

Record last verified: 2016-05

Locations

LI (2); RO (6); RU (6); SL (1); UA (5); AU (5); PL (6); BU (5); CR (1)